Cargando…

Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study

OBJECTIVE: The purpose of this study is both to estimate the efficacy and the safety of Yukgunja-tang (YGJT) and to establish evidence for the use of herbal medicines in the management of patients with cancer-related anorexia. METHODS: We enrolled 40 patients with cancer-related anorexia. The enroll...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Myung-Hyun, Song, Si-Yeon, Ha, Su-Jeong, Lee, Jee Young, Yoon, Seong Woo, Park, Ji-Hye, Park, So-Jung, Yoo, Hwa-Seung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371029/
https://www.ncbi.nlm.nih.gov/pubmed/34032151
http://dx.doi.org/10.1177/15347354211019107
_version_ 1783739557353619456
author Ko, Myung-Hyun
Song, Si-Yeon
Ha, Su-Jeong
Lee, Jee Young
Yoon, Seong Woo
Park, Ji-Hye
Park, So-Jung
Yoo, Hwa-Seung
author_facet Ko, Myung-Hyun
Song, Si-Yeon
Ha, Su-Jeong
Lee, Jee Young
Yoon, Seong Woo
Park, Ji-Hye
Park, So-Jung
Yoo, Hwa-Seung
author_sort Ko, Myung-Hyun
collection PubMed
description OBJECTIVE: The purpose of this study is both to estimate the efficacy and the safety of Yukgunja-tang (YGJT) and to establish evidence for the use of herbal medicines in the management of patients with cancer-related anorexia. METHODS: We enrolled 40 patients with cancer-related anorexia. The enrolled participants were randomly allocated to 2 groups: the control group (n = 20), which received nutrition counseling, and the treatment group (n = 20), which received nutrition counseling and was administered YGJT at twice a day for 4 weeks (a total of 56 times @ 3.0 g each time). The primary outcome of this study was the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes were the FAACT score with the ACS score excluded, the score on the Visual Analog Scale (VAS) for appetite, and the results on laboratory tests regarding appetite, such as leptin, tumor necrosis factors (TNF-α), interleukin-6 (IL-6), and ghrelin. All variables related to the safety assessment, such as vital signs, electrocardiography results, laboratory test results (complete blood cell count, chemistry, urine test), and adverse events, were documented on the case report form (CRF) at every visit. RESULT: The difference in the primary outcome, that is, the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT), between the control and the treatment groups was statistically significant (P = .023) as was the difference in the FAACT scores with the ACS score excluded, a secondary outcome, between the 2 groups; however, no statistically significant differences were noted in the scores on the VAS or the levels of leptin, TNF-α, IL-6, and ghrelin. In addition, no significant differences in the numbers and the types of adverse events or in the results on the laboratory tests between the control and the treatment groups were recorded. CONCLUSION: These results obtained in this research confirmed the efficacy and the safety of using YGJT as a herb-medicine treatment option for patients with cancer-related anorexia.
format Online
Article
Text
id pubmed-8371029
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-83710292021-08-19 Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study Ko, Myung-Hyun Song, Si-Yeon Ha, Su-Jeong Lee, Jee Young Yoon, Seong Woo Park, Ji-Hye Park, So-Jung Yoo, Hwa-Seung Integr Cancer Ther Research Article OBJECTIVE: The purpose of this study is both to estimate the efficacy and the safety of Yukgunja-tang (YGJT) and to establish evidence for the use of herbal medicines in the management of patients with cancer-related anorexia. METHODS: We enrolled 40 patients with cancer-related anorexia. The enrolled participants were randomly allocated to 2 groups: the control group (n = 20), which received nutrition counseling, and the treatment group (n = 20), which received nutrition counseling and was administered YGJT at twice a day for 4 weeks (a total of 56 times @ 3.0 g each time). The primary outcome of this study was the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes were the FAACT score with the ACS score excluded, the score on the Visual Analog Scale (VAS) for appetite, and the results on laboratory tests regarding appetite, such as leptin, tumor necrosis factors (TNF-α), interleukin-6 (IL-6), and ghrelin. All variables related to the safety assessment, such as vital signs, electrocardiography results, laboratory test results (complete blood cell count, chemistry, urine test), and adverse events, were documented on the case report form (CRF) at every visit. RESULT: The difference in the primary outcome, that is, the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT), between the control and the treatment groups was statistically significant (P = .023) as was the difference in the FAACT scores with the ACS score excluded, a secondary outcome, between the 2 groups; however, no statistically significant differences were noted in the scores on the VAS or the levels of leptin, TNF-α, IL-6, and ghrelin. In addition, no significant differences in the numbers and the types of adverse events or in the results on the laboratory tests between the control and the treatment groups were recorded. CONCLUSION: These results obtained in this research confirmed the efficacy and the safety of using YGJT as a herb-medicine treatment option for patients with cancer-related anorexia. SAGE Publications 2021-05-25 /pmc/articles/PMC8371029/ /pubmed/34032151 http://dx.doi.org/10.1177/15347354211019107 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Article
Ko, Myung-Hyun
Song, Si-Yeon
Ha, Su-Jeong
Lee, Jee Young
Yoon, Seong Woo
Park, Ji-Hye
Park, So-Jung
Yoo, Hwa-Seung
Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study
title Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study
title_full Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study
title_fullStr Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study
title_full_unstemmed Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study
title_short Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study
title_sort efficacy and safety of yukgunja-tang for patients with cancer-related anorexia: a randomized, controlled trial, pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371029/
https://www.ncbi.nlm.nih.gov/pubmed/34032151
http://dx.doi.org/10.1177/15347354211019107
work_keys_str_mv AT komyunghyun efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy
AT songsiyeon efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy
AT hasujeong efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy
AT leejeeyoung efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy
AT yoonseongwoo efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy
AT parkjihye efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy
AT parksojung efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy
AT yoohwaseung efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy